Recording available for the “Long-term treatment & DDI implications in the management of CAT”
You can now watch the recording of “Long-term treatment & DDI implications in the management of...
AUTHORS
ICTHIC Editorial Office
ICTHIC Editorial Office is based in Milan, Italy, c/o Polistudium srl.
Sara di Nunzio, Italy, Managing Editor
Aashni Shah, UK, Editor
Francesca Cappellini, Italy, Medical Writer and Social Media Manager
Massimiliano Pianta, Italy, Graphic Designer
Giorgio Maitti, IT Developer
Phone +39 3714686513
email: editorialoffice@magazine.icthic.com
Sara di Nunzio, Italy, Managing Editor
Aashni Shah, UK, Editor
Francesca Cappellini, Italy, Medical Writer and Social Media Manager
Massimiliano Pianta, Italy, Graphic Designer
Giorgio Maitti, IT Developer
Phone +39 3714686513
email: editorialoffice@magazine.icthic.com
Real-world CAT patient profile from the RIETE registry
During the ICTHIC webinar, “What is the profile of the real-world CAT patient?”, Dr. Laurent Bertoletti gave a...
Chronic Kidney disease in CAT patients
During the ICTHIC webinar, “What is the profile of the real-world CAT patient?” Dr. Corinne Isnard Bagnis gave a...
Updates in cancer-associated thrombosis
Our speakers, Luis Jara Palomares, Nikolaos Tsoukalas, and Nuria Muñoz Rivas, shared some updates on...
COVID-19-associated coagulopathy and thrombosis in cancer
During the 11th ICTHIC, Marcel M Levi talked about COVID-19 thrombotic implications in patients with cancer. Here, we...
What is the profile of the Real-World CAT patient?
Our speakers, Laurent Bertoletti, Corinne Frere and Corinne Isnard Bagnis, shared some insights on the...
Recording available for the webinar “Updates in Cancer-Associated Thrombosis”
You can now watch the recording of “updates in cancer-associated thrombosis” webinar. Check...
Cancer genetic alterations and risk of venous thromboembolism
During the 11th ICTHIC, Simon Mantha talked about the relationship between genetic cancer alteration and the risk of...
PODCAST. Drug-drug interactions: Implications for anticoagulation use in patients with cancer
Cancer patients have an increased risk of VTE by at least 12-fold, and cancer therapies increase the risk of VTE by a...
DEBATE: Should VTE treatment continue beyond six months? The evidence behind the decision to continue anticoagulation
During the 11th ICTHIC, Agnes YY Lee and Marcello Di Nisio debated whether anticoagulation treatment should be...